ASCO 2023

ADC revolution: How can the new results be integrated…

CDK4/6i in EBC: Have abema and ribo arrived in the…

Sonia trial: How does the new data change clinical…

Expanding CDK4/6i therapy in EBC: How to select…

PART1: How to de-escalate chemotherapy? What is the…

CDK4/6 inhibitors in EBC: Amazing data, but longer…

Chemotherapy de-escalation in HER2+ patients:…

Data from Meta-Analyses of almost 15k Patients: Who…

Ovarian function - Ovarian suppression not necessary in…

10 years update on ShortHER

Ribociclib has arrived in the adjuvant setting

De-escalation of CT for early BC

From PENELOPE-B to SURVIVE

SOC of ovarian ablation confirmed in meta-analysis.

Early follow-up shows clear benefit

TILs in HER2+ disease - prognostic, but not enough to…

Another proof of efficacy of immunotherapy in advanced…

A challenge for clinical management

Analyses of ctDNA in PENELOPE-B: Test methods are…

My EBC highlights from ASCO23

More CDK4/6 options for EBC patients

TILs are prognostic but not predictive in HER2+ EBC

Palbociclib after Palbociclib might not be the best…

Chemo-immunotherapeutic signals especially in HER2low…

PHERGain opens the possibility to avoid chemotherapy in…

Discussions on CDK4/6 inhibitors in EBC

Tumor-informed ctDNA likely prognostic for relapse in…

1/3 of patients with HER2+ in future without…

White blood cells with increasing prognostic relevance?…

TILs subtypes are associated with clinical features and…

Response adapted, chemotherapy-free option in HER2+ EBC

First data with adjuvant ribociclib

Young patients benefit from ovarian suppression

Can we preserve our patients form chemotherapy?

Checkpoint inhibition in endometrial cancer: new…

Practice changing or not quite yet?

I miei punti salienti di ASCO23

Eine Herausforderung für viele Patienten, wenig…

Palbociclib después de Palbociclib podría no ser la…

NATALEE nicht überraschend aber überzeugend positiv

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

TILs w rakach HER2+ - znaczenie rokownicze, ale nie…

Kolejny dowód na skuteczność immunoterapii w…

PHERGain abre la posibilidad de evitar la quimioterapia…

Tumor-informed ctDNA wahrscheinlich prognostisch für…

1/3 der Patientinnen mit HER2+ zukünftig ohne…

Von PENELOPE-B zur SURVIVE

Primele date cu ribociclib adjuvant

Eine Herausforderung für das klinische Management

Czy wystarczy, aby zmienić standardy?

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

Response adaptierte, Chemotherapie-freie Option beim…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

E-Health Applications in Oral Cancer Therapy

Updates on ADCs in metastatic breast cancer

The start of precision medicine in HR+ breast cancer

Continued OS benefit for Sacituzumab Govitecan

What is the optimal therapie sequence for HR+ MBC…

Aggiornamenti sugli ADC nel carcinoma mammario…

Mises à jour sur les ADC dans le cancer du sein…

Update ADC efficacy

CDK4/6i in first line and beyond & Biomarkers

CDK4/6 Sequencing? ESR-1 not ready for prime time?…

PRL-02: Intramuscular arbiraterone

Metastasis-directed for prostate cancer

ARASEC: ADT + Daralutamide for mHSPC

PEACE 1 - results and controversies

Part2: Important update on testosterone-recovery

Reassuring real-world data!

DEAR trial: real-world comparator analyses of ARIs

Intensified or de-intensified therapy in mHSPC

PSA nadir 6 month after Radiotherapy is strong…

PAPR-inhibitors: Patient-selection matters!

AI for prediction in local prostate carcinoma

Part 1: Important update on testosterone-recovery

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Confirming results for PARPi in mCRPC

Over-staging of bone scan compared with PSMA PET/CT

PSA nadir 6 månader efter radioterapi är en prognostisk…

Intensifierad eller de-intensifierad behandling vid…

PARP-inhibitors: La selección de pacientes es…

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

What is your preferred sequence in 1st line treatment…

Triple therapy in mCSPC - which is the ideal partner…

Best of Bladder: ddMVC increases DFS! Standard…

Q-TWiST in the therapy of aUC

Extent of lymphadenectomy in cystectomy

New standard for MIBC

Enfortumab vedotin + pembrolizumab 1stL in…

FGFR inhibition

Targeted therapies in advanced urothelial cancer: The…

First line in cisplatin-ineligible advance urothelial…

New SoC option for metastatic bladder cancer

Primera línea en cáncer urotelial avanzado no elegible…

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…

Nouvelles options de soins standard pour le cancer de…

The efficacy of neo-adjuvant therapy (ddMVAC,…

The efficacy of FGFR targeting

The impact of microbiome and supplements on therapy…

Long term follow up in advanced renal cell cancer: Is…

Non ccRCC: how should we treat patients today?

New data non ccRCC

News from the adjuvant

1st Line therapy RCC: which combination to choose?

IO rechallenge in mRCC

Update and take home message of 1st Line mRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell…

Long-term follow-up for IO/TKI in mRCC

The value of perioperative chemo-IO in rNSCLC and the…

ADAURA - Discussion closed?

Adjuvant and neoadjuvant strategies in resectable NSCLC

Confirmation of neoadjuvant immunotherapy

More options in the perioperative setting

A new standard of care for operated patients with…

Role of periopertative IO confirmed

A new standard of care

Which should we prefer: neoadjuvant, adjuvant or…

Another neoadjuvant chemo/IO option

CheckMate 9LA: 4‑year clinical update

Perioperative treatment

ADAURA - results and controversies

Adjuvant IO in KRASm patients

Induction options in the perioperative setting

A chemo-free preop. IO strategy?

OS benefit from EGFR receptor TKI

Added benefit of perioperative chemo/IO in stage 2-3b…

EGFR testing necessary in the adjuvant setting

Rolle der periopertativen IO bestätigt

Stratégies adjuvantes et néoadjuvantes dans le CBNPC…

ADAURA- discussie gesloten?

Toegevoegde waarde van periperatief chemo-immuno bij…

Un nouveau standard therapeutique pour les patients…

Más opciones en el entorno perioperatorio

Sotorasib: clear clinical benefit, but short follow-up…

Zorifertinib: an option when osimertinib is not…

TTF-treatment requires further studies

Update on KRASG12Cm treatment options - how to proceed?

Pembro + chemo in pts with TKI-resistant EGFRm /…

LUNAR: TTF medical device shows OS-benefit, but more…

ADC + ICI ± Pt-CT in patients with aNSCLC

CORRELATE - a real world analysis

TROP2-ADC shows high response rates in 1L-combination…

Stopping treatment is ok

New data from another BiTE

Treatment strategies in SCLC

Hyperfractionated radiotherapy for SCLC

Can we incoporate biomarkers in SCLC treatment?

A positive trial with no impact

Stratégies de traitement dans le SCLC

Kunnen we biomarkers gebruiken om behandeling te…

ONCOalert (inclusive patient advocates) consensus on…

Immune checkpoint inhibitors in malignant mesothelioma